Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 10/20 | 0.61 |
| ▸ | HTR1A | P08908 | 2/20 | 0.55 |
| ▸ | HTR2A | P28223 | 2/20 | 0.55 |
| ▸ | HTR2C | P28335 | 2/20 | 0.55 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.54 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | HTR6 | P50406 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2137773 | 0.99 | HTR7 (0.60) | HTR7HTR1AHTR2AHTR2CABCB1 | |
| SCHEMBL5402012 | 0.92 | HTR7 (0.71) | HTR7ABCB1 | |
| SCHEMBL10035595 | 0.91 | ABCB1 (0.64) | HTR7HTR1AHTR2AHTR2CABCB1 | |
| SCHEMBL10035562 | 0.90 | HTR7 (0.63) | HTR7HTR1AHTR2AHTR2CABCB1 | |
| Hydrochloric Acid SCHEMBL2141854 | 0.90 | ABCB1 (0.63) | HTR7HTR1AHTR2AHTR2CABCB1 | |
| Hydrochloric Acid SCHEMBL2141212 | 0.89 | HTR7 (0.62) | HTR7ABCB1DRD2 | |
| SCHEMBL8983429 | 0.89 | HTR7 (0.72) | HTR7ABCB1DRD2HTR6 | |
| SCHEMBL8983540 | 0.88 | ABCB1 (0.61) | HTR7HTR1AHTR2AHTR2CABCB1 | |
| Hydrochloric Acid SCHEMBL4218491 | 0.88 | HTR7 (0.71) | HTR7ABCB1DRD2HTR6 | |
| SCHEMBL8981592 | 0.87 | HTR7 (0.64) | HTR7ABCB1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148397-B2 | 5-HT7 receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-04-03 | — | — | US | disclosed |
| US-8148397-B2 | 5-HT7 receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-04-03 | — | — | US | disclosed |
| US-20090088450-A1 | 5-ht7 receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-04-02 | — | — | US | disclosed |
| US-20090088450-A1 | 5-ht7 receptor antagonists | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088450-A1 | 5-ht7 receptor antagonists | HTR7, HTR1A, HTR5A | HTR7 1/4885HTR1A 2/4885HTR2A 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.